Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Evdokia ANAGNOSTOU |
Documents disponibles écrits par cet auteur (64)
Faire une suggestion Affiner la recherche
Physical activity participation among adolescents with autism spectrum disorder / Patrick JACHYRA in Autism, 25-3 (April 2021)
[article]
Titre : Physical activity participation among adolescents with autism spectrum disorder Type de document : Texte imprimé et/ou numérique Auteurs : Patrick JACHYRA, Auteur ; Rebecca RENWICK, Auteur ; Brenda GLADSTONE, Auteur ; Evdokia ANAGNOSTOU, Auteur ; Barbara E GIBSON, Auteur Article en page(s) : p.613-626 Langues : Anglais (eng) Mots-clés : adolescents autism spectrum disorder digital storytelling physical activity physical health qualitative research Index. décimale : PER Périodiques Résumé : Adolescents with autism spectrum disorder are less likely to be physically active compared to their age-related peers. Despite the lower levels of physical activity observed among adolescents with autism spectrum disorder, it is unknown why they are predominantly inactive. Much of the research so far has focused on understanding how biological aspects influence physical activity participation. But there is little research that has examined how social and cultural components influence their physical activity participation. There is also little research that has sought the perspectives and experiences of adolescents with autism spectrum disorder. In this study, 10 adolescent boys with autism spectrum disorder created a digital story, and also participated in two face-to-face interviews. The purpose of the study was to examine how individual, social, and cultural forces influenced physical activity participation. Analysis of the data highlight that bullying, challenges in community programs, and the prioritization of therapeutic interventions limited participation. On the contrary, participants were more likely to be active when physical activity generated meaning, purpose, a sense of identity, and affective pleasures. The findings add new knowledge suggesting that adolescents with autism spectrum disorder are not simply unmotivated. Rather, physical activity participation was shaped by wider social experiences, norms, values, and practices in which they were immersed. The findings suggest a need for directed efforts to create policies and practices which are individualized and reflective of the needs and abilities of adolescents with autism spectrum disorder to promote physical activity participation and potentially enhance physical health and wellbeing. En ligne : http://dx.doi.org/10.1177/1362361320949344 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=444
in Autism > 25-3 (April 2021) . - p.613-626[article] Physical activity participation among adolescents with autism spectrum disorder [Texte imprimé et/ou numérique] / Patrick JACHYRA, Auteur ; Rebecca RENWICK, Auteur ; Brenda GLADSTONE, Auteur ; Evdokia ANAGNOSTOU, Auteur ; Barbara E GIBSON, Auteur . - p.613-626.
Langues : Anglais (eng)
in Autism > 25-3 (April 2021) . - p.613-626
Mots-clés : adolescents autism spectrum disorder digital storytelling physical activity physical health qualitative research Index. décimale : PER Périodiques Résumé : Adolescents with autism spectrum disorder are less likely to be physically active compared to their age-related peers. Despite the lower levels of physical activity observed among adolescents with autism spectrum disorder, it is unknown why they are predominantly inactive. Much of the research so far has focused on understanding how biological aspects influence physical activity participation. But there is little research that has examined how social and cultural components influence their physical activity participation. There is also little research that has sought the perspectives and experiences of adolescents with autism spectrum disorder. In this study, 10 adolescent boys with autism spectrum disorder created a digital story, and also participated in two face-to-face interviews. The purpose of the study was to examine how individual, social, and cultural forces influenced physical activity participation. Analysis of the data highlight that bullying, challenges in community programs, and the prioritization of therapeutic interventions limited participation. On the contrary, participants were more likely to be active when physical activity generated meaning, purpose, a sense of identity, and affective pleasures. The findings add new knowledge suggesting that adolescents with autism spectrum disorder are not simply unmotivated. Rather, physical activity participation was shaped by wider social experiences, norms, values, and practices in which they were immersed. The findings suggest a need for directed efforts to create policies and practices which are individualized and reflective of the needs and abilities of adolescents with autism spectrum disorder to promote physical activity participation and potentially enhance physical health and wellbeing. En ligne : http://dx.doi.org/10.1177/1362361320949344 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=444 A pilot dose finding study of pioglitazone in autistic children / L. CAPANO in Molecular Autism, 9 (2018)
[article]
Titre : A pilot dose finding study of pioglitazone in autistic children Type de document : Texte imprimé et/ou numérique Auteurs : L. CAPANO, Auteur ; A. DUPUIS, Auteur ; Jessica BRIAN, Auteur ; D. MANKAD, Auteur ; L. GENORE, Auteur ; R. HASTIE ADAMS, Auteur ; S. SMILE, Auteur ; T. LUI, Auteur ; D. ODROBINA, Auteur ; J. A. FOSTER, Auteur ; Evdokia ANAGNOSTOU, Auteur Article en page(s) : 59p. Langues : Anglais (eng) Mots-clés : Autism spectrum disorder Clinical trial Cytokines Drug therapy Efficacy Inflammation Maximum tolerated dose (MTD) Physiological effects of drugs Pioglitazone Safety profile Treatment Index. décimale : PER Périodiques Résumé : Background: Pioglitazone is a promising compound for treatment of core autism spectrum disorder (ASD) symptoms as it targets multiple relevant pathways, including immune system alterations. Objective: This pilot study aimed to elucidate the maximum tolerated dose, safety, preliminary evidence of efficacy, and appropriate outcome measures in autistic children ages 5-12 years old. Methods: We conducted a 16-week prospective cohort, single blind, single arm, 2-week placebo run-in, dose-finding study of pioglitazone. Twenty-five participants completed treatment. A modified dose finding method was used to determine safety and dose response among three dose levels: 0.25 mg/kg, 0.5 mg/kg, and 0.75 mg/kg once daily. Results: Maximum tolerated dose: there were no serious adverse events (SAEs) and as such the maximum tolerated dose within the range tested was 0.75 mg/Kg once daily.Safety: overall, pioglitazone was well tolerated. Two participants discontinued intervention due to perceived non-efficacy and one due to the inability to tolerate interim blood work. Three participants experienced mild neutropenia.Early evidence of efficacy: statistically significant improvement was observed in social withdrawal, repetitive behaviors, and externalizing behaviors as measured by the Aberrant Behavior Checklist (ABC), Child Yale-Brown Obsessive Compulsive Scale (CY-BOCS), and Repetitive Behavior Scale-Revised (RBS-R). Forty-six percent of those enrolled were deemed to be global responders. Conclusions and relevance: Pioglitazone is well-tolerated and shows a potential signal in measures of social withdrawal, repetitive, and externalizing behaviors. Randomized controlled trials using the confirmed dose are warranted. Trial registration: ClinicalTrials.gov, NCT01205282. Registration date: September 20, 2010. En ligne : https://dx.doi.org/10.1186/s13229-018-0241-5 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=371
in Molecular Autism > 9 (2018) . - 59p.[article] A pilot dose finding study of pioglitazone in autistic children [Texte imprimé et/ou numérique] / L. CAPANO, Auteur ; A. DUPUIS, Auteur ; Jessica BRIAN, Auteur ; D. MANKAD, Auteur ; L. GENORE, Auteur ; R. HASTIE ADAMS, Auteur ; S. SMILE, Auteur ; T. LUI, Auteur ; D. ODROBINA, Auteur ; J. A. FOSTER, Auteur ; Evdokia ANAGNOSTOU, Auteur . - 59p.
Langues : Anglais (eng)
in Molecular Autism > 9 (2018) . - 59p.
Mots-clés : Autism spectrum disorder Clinical trial Cytokines Drug therapy Efficacy Inflammation Maximum tolerated dose (MTD) Physiological effects of drugs Pioglitazone Safety profile Treatment Index. décimale : PER Périodiques Résumé : Background: Pioglitazone is a promising compound for treatment of core autism spectrum disorder (ASD) symptoms as it targets multiple relevant pathways, including immune system alterations. Objective: This pilot study aimed to elucidate the maximum tolerated dose, safety, preliminary evidence of efficacy, and appropriate outcome measures in autistic children ages 5-12 years old. Methods: We conducted a 16-week prospective cohort, single blind, single arm, 2-week placebo run-in, dose-finding study of pioglitazone. Twenty-five participants completed treatment. A modified dose finding method was used to determine safety and dose response among three dose levels: 0.25 mg/kg, 0.5 mg/kg, and 0.75 mg/kg once daily. Results: Maximum tolerated dose: there were no serious adverse events (SAEs) and as such the maximum tolerated dose within the range tested was 0.75 mg/Kg once daily.Safety: overall, pioglitazone was well tolerated. Two participants discontinued intervention due to perceived non-efficacy and one due to the inability to tolerate interim blood work. Three participants experienced mild neutropenia.Early evidence of efficacy: statistically significant improvement was observed in social withdrawal, repetitive behaviors, and externalizing behaviors as measured by the Aberrant Behavior Checklist (ABC), Child Yale-Brown Obsessive Compulsive Scale (CY-BOCS), and Repetitive Behavior Scale-Revised (RBS-R). Forty-six percent of those enrolled were deemed to be global responders. Conclusions and relevance: Pioglitazone is well-tolerated and shows a potential signal in measures of social withdrawal, repetitive, and externalizing behaviors. Randomized controlled trials using the confirmed dose are warranted. Trial registration: ClinicalTrials.gov, NCT01205282. Registration date: September 20, 2010. En ligne : https://dx.doi.org/10.1186/s13229-018-0241-5 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=371 Practice patterns and determinants of wait time for autism spectrum disorder diagnosis in Canada / M. PENNER in Molecular Autism, 9 (2018)
[article]
Titre : Practice patterns and determinants of wait time for autism spectrum disorder diagnosis in Canada Type de document : Texte imprimé et/ou numérique Auteurs : M. PENNER, Auteur ; Evdokia ANAGNOSTOU, Auteur ; W. J. UNGAR, Auteur Article en page(s) : 16p. Langues : Anglais (eng) Mots-clés : Autism spectrum disorder Diagnosis Early detection Health services research Pediatrics Index. décimale : PER Périodiques Résumé : Background: Inefficient diagnostic practices for autism spectrum disorder (ASD) may contribute to longer wait times, delaying access to intervention. The objectives were to describe the diagnostic practices of Canadian pediatricians and to identify determinants of longer wait time for ASD diagnosis. Methods: An online survey was conducted through the Canadian Paediatric Society's developmental pediatrics, community pediatrics, and mental health sections. Participants were asked for demographic information, whether they diagnosed ASD, and elements of their diagnostic assessment. A multiple linear regression of total wait time (time from referral to communication of the diagnosis to the family) as a function of practice characteristics was conducted. Results: A total of 90 participants completed the survey, of whom 57 diagnosed ASD in their practices (63.3%). Respondents reported varied use of multi-disciplinary teams, with 53% reporting participation in a team. No two identically composed teams were reported. Respondents also had varied use of diagnostic tools, with 21% reporting no use of tools. The median reported total wait for ASD diagnosis time was 7 months (interquartile range 4-12 months). Longer time spent on assessment was the only variable that remained significantly associated with longer wait time in multiple regression (p = 0.002). Use of diagnostic tools did not significantly affect wait time. Conclusion: Canadian ASD diagnostic practices vary widely and wait times for these assessments are substantial-7 months from referral to receipt of diagnosis. Time spent on the assessment is a significant determinant of wait time, highlighting the need for efficient assessment practices. En ligne : http://dx.doi.org/10.1186/s13229-018-0201-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=354
in Molecular Autism > 9 (2018) . - 16p.[article] Practice patterns and determinants of wait time for autism spectrum disorder diagnosis in Canada [Texte imprimé et/ou numérique] / M. PENNER, Auteur ; Evdokia ANAGNOSTOU, Auteur ; W. J. UNGAR, Auteur . - 16p.
Langues : Anglais (eng)
in Molecular Autism > 9 (2018) . - 16p.
Mots-clés : Autism spectrum disorder Diagnosis Early detection Health services research Pediatrics Index. décimale : PER Périodiques Résumé : Background: Inefficient diagnostic practices for autism spectrum disorder (ASD) may contribute to longer wait times, delaying access to intervention. The objectives were to describe the diagnostic practices of Canadian pediatricians and to identify determinants of longer wait time for ASD diagnosis. Methods: An online survey was conducted through the Canadian Paediatric Society's developmental pediatrics, community pediatrics, and mental health sections. Participants were asked for demographic information, whether they diagnosed ASD, and elements of their diagnostic assessment. A multiple linear regression of total wait time (time from referral to communication of the diagnosis to the family) as a function of practice characteristics was conducted. Results: A total of 90 participants completed the survey, of whom 57 diagnosed ASD in their practices (63.3%). Respondents reported varied use of multi-disciplinary teams, with 53% reporting participation in a team. No two identically composed teams were reported. Respondents also had varied use of diagnostic tools, with 21% reporting no use of tools. The median reported total wait for ASD diagnosis time was 7 months (interquartile range 4-12 months). Longer time spent on assessment was the only variable that remained significantly associated with longer wait time in multiple regression (p = 0.002). Use of diagnostic tools did not significantly affect wait time. Conclusion: Canadian ASD diagnostic practices vary widely and wait times for these assessments are substantial-7 months from referral to receipt of diagnosis. Time spent on the assessment is a significant determinant of wait time, highlighting the need for efficient assessment practices. En ligne : http://dx.doi.org/10.1186/s13229-018-0201-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=354 Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis / R. RODRIGUES in Journal of Child Psychology and Psychiatry, 62-6 (June 2021)
[article]
Titre : Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis Type de document : Texte imprimé et/ou numérique Auteurs : R. RODRIGUES, Auteur ; Meng-Chuan LAI, Auteur ; A. BESWICK, Auteur ; D. A. GORMAN, Auteur ; Evdokia ANAGNOSTOU, Auteur ; P. SZATMARI, Auteur ; K. K. ANDERSON, Auteur ; Stephanie H. AMEIS, Auteur Article en page(s) : p.680-700 Langues : Anglais (eng) Mots-clés : Adolescent Atomoxetine Hydrochloride/therapeutic use Attention Deficit Disorder with Hyperactivity/drug therapy Autism Spectrum Disorder/drug therapy Central Nervous System Stimulants/adverse effects Child Guanfacine Humans Methylphenidate/adverse effects Adhd Attention-deficit/hyperactivity disorder alpha-2 agonists antipsychotics atomoxetine autism spectrum disorder bupropion hyperactivity impulsivity inattention modafinil. pervasive developmental disorder pharmacotherapy stimulants tricyclic antidepressants venlafaxine Index. décimale : PER Périodiques Résumé : BACKGROUND: Clinically significant attention-deficit/hyperactivity disorder (ADHD) symptoms are common and impairing in children and youth with autism spectrum disorder(ASD). The aim of this systematic review and meta-analysis was to (a) evaluate the efficacy and safety of pharmacotherapy for the treatment of ADHD symptoms in ASD and (b) distil findings for clinical translation. METHODS: We searched electronic databases and clinical trial registries (1992 onwards). We selected randomized controlled trials conducted in participants <25 years of age, diagnosed with ASD that evaluated ADHD outcomes (hyperactivity/impulsivity and inattention) following treatment with stimulants (methylphenidate or amphetamines), atomoxetine, alpha-2 adrenergic receptor agonists, antipsychotics, tricyclic antidepressants, bupropion, modafinil, venlafaxine, or a combination, in comparison with placebo, any of the listed medications, or behavioral therapies. Data were pooled using a random-effects model. RESULTS: Twenty-five studies (4 methylphenidate, 4 atomoxetine, 1 guanfacine, 14 antipsychotic, 1 venlafaxine, and 1 tianeptine) were included. Methylphenidate reduced hyperactivity (parent-rated: standardized mean difference [SMD] = -.63, 95%CI = -.95,-.30; teacher-rated: SMD = -.81, 95%CI = -1.43,-.19) and inattention (parent-rated: SMD = -.36, 95%CI = -.64,-.07; teacher-rated: SMD = -.30, 95%CI = -.49,-.11). Atomoxetine reduced inattention (parent-rated: SMD = -.54, 95%CI = -.98,-.09; teacher/investigator-rated: SMD = -0.38, 95%CI = -0.75, -0.01) and parent-rated hyperactivity (parent-rated: SMD = -.49, 95%CI = -.76,-.23; teacher-rated: SMD = -.43, 95%CI = -.92, .06). Indirect evidence for significant reductions in hyperactivity with second-generation antipsychotics was also found. Quality of evidence for all interventions was low/very low. Methylphenidate was associated with a nonsignificant elevated risk of dropout due to adverse events. CONCLUSIONS: Direct pooled evidence supports the efficacy and tolerability of methylphenidate or atomoxetine for treatment of ADHD symptoms in children and youth with ASD. The current review highlights the efficacy of standard ADHD pharmacotherapy for treatment of ADHD symptoms in children and youth with ASD. Consideration of the benefits weighed against the limitations of safety/efficacy data and lack of data evaluating long-term continuation is undertaken to help guide clinical decision-making regarding treatment of co-occurring ADHD symptoms in children and youth with ASD. En ligne : http://dx.doi.org/10.1111/jcpp.13305 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=455
in Journal of Child Psychology and Psychiatry > 62-6 (June 2021) . - p.680-700[article] Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis [Texte imprimé et/ou numérique] / R. RODRIGUES, Auteur ; Meng-Chuan LAI, Auteur ; A. BESWICK, Auteur ; D. A. GORMAN, Auteur ; Evdokia ANAGNOSTOU, Auteur ; P. SZATMARI, Auteur ; K. K. ANDERSON, Auteur ; Stephanie H. AMEIS, Auteur . - p.680-700.
Langues : Anglais (eng)
in Journal of Child Psychology and Psychiatry > 62-6 (June 2021) . - p.680-700
Mots-clés : Adolescent Atomoxetine Hydrochloride/therapeutic use Attention Deficit Disorder with Hyperactivity/drug therapy Autism Spectrum Disorder/drug therapy Central Nervous System Stimulants/adverse effects Child Guanfacine Humans Methylphenidate/adverse effects Adhd Attention-deficit/hyperactivity disorder alpha-2 agonists antipsychotics atomoxetine autism spectrum disorder bupropion hyperactivity impulsivity inattention modafinil. pervasive developmental disorder pharmacotherapy stimulants tricyclic antidepressants venlafaxine Index. décimale : PER Périodiques Résumé : BACKGROUND: Clinically significant attention-deficit/hyperactivity disorder (ADHD) symptoms are common and impairing in children and youth with autism spectrum disorder(ASD). The aim of this systematic review and meta-analysis was to (a) evaluate the efficacy and safety of pharmacotherapy for the treatment of ADHD symptoms in ASD and (b) distil findings for clinical translation. METHODS: We searched electronic databases and clinical trial registries (1992 onwards). We selected randomized controlled trials conducted in participants <25 years of age, diagnosed with ASD that evaluated ADHD outcomes (hyperactivity/impulsivity and inattention) following treatment with stimulants (methylphenidate or amphetamines), atomoxetine, alpha-2 adrenergic receptor agonists, antipsychotics, tricyclic antidepressants, bupropion, modafinil, venlafaxine, or a combination, in comparison with placebo, any of the listed medications, or behavioral therapies. Data were pooled using a random-effects model. RESULTS: Twenty-five studies (4 methylphenidate, 4 atomoxetine, 1 guanfacine, 14 antipsychotic, 1 venlafaxine, and 1 tianeptine) were included. Methylphenidate reduced hyperactivity (parent-rated: standardized mean difference [SMD] = -.63, 95%CI = -.95,-.30; teacher-rated: SMD = -.81, 95%CI = -1.43,-.19) and inattention (parent-rated: SMD = -.36, 95%CI = -.64,-.07; teacher-rated: SMD = -.30, 95%CI = -.49,-.11). Atomoxetine reduced inattention (parent-rated: SMD = -.54, 95%CI = -.98,-.09; teacher/investigator-rated: SMD = -0.38, 95%CI = -0.75, -0.01) and parent-rated hyperactivity (parent-rated: SMD = -.49, 95%CI = -.76,-.23; teacher-rated: SMD = -.43, 95%CI = -.92, .06). Indirect evidence for significant reductions in hyperactivity with second-generation antipsychotics was also found. Quality of evidence for all interventions was low/very low. Methylphenidate was associated with a nonsignificant elevated risk of dropout due to adverse events. CONCLUSIONS: Direct pooled evidence supports the efficacy and tolerability of methylphenidate or atomoxetine for treatment of ADHD symptoms in children and youth with ASD. The current review highlights the efficacy of standard ADHD pharmacotherapy for treatment of ADHD symptoms in children and youth with ASD. Consideration of the benefits weighed against the limitations of safety/efficacy data and lack of data evaluating long-term continuation is undertaken to help guide clinical decision-making regarding treatment of co-occurring ADHD symptoms in children and youth with ASD. En ligne : http://dx.doi.org/10.1111/jcpp.13305 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=455 A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism / Deepali MANKAD in Molecular Autism, (March 2015)
[article]
Titre : A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism Type de document : Texte imprimé et/ou numérique Auteurs : Deepali MANKAD, Auteur ; Annie DUPUIS, Auteur ; Sharon SMILE, Auteur ; Wendy ROBERTS, Auteur ; Jessica BRIAN, Auteur ; Toni LUI, Auteur ; Lisa GENORE, Auteur ; Dina ZAGHLOUL, Auteur ; Alana IABONI, Auteur ; Peggy Margaret A. MARCON, Auteur ; Evdokia ANAGNOSTOU, Auteur Article en page(s) : p.1-11 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Autism spectrum disorder (ASD) is a neurodevelopmental disorder affecting more than 1% of children. It is characterized by social communication deficits and repetitive behaviors/restricted interests. In the absence of any medications known to improve core symptom domains, parents often use complementary alternative treatments, including omega-3 fatty acid supplements. En ligne : http://dx.doi.org/10.1186/s13229-015-0010-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=277
in Molecular Autism > (March 2015) . - p.1-11[article] A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism [Texte imprimé et/ou numérique] / Deepali MANKAD, Auteur ; Annie DUPUIS, Auteur ; Sharon SMILE, Auteur ; Wendy ROBERTS, Auteur ; Jessica BRIAN, Auteur ; Toni LUI, Auteur ; Lisa GENORE, Auteur ; Dina ZAGHLOUL, Auteur ; Alana IABONI, Auteur ; Peggy Margaret A. MARCON, Auteur ; Evdokia ANAGNOSTOU, Auteur . - p.1-11.
Langues : Anglais (eng)
in Molecular Autism > (March 2015) . - p.1-11
Index. décimale : PER Périodiques Résumé : Autism spectrum disorder (ASD) is a neurodevelopmental disorder affecting more than 1% of children. It is characterized by social communication deficits and repetitive behaviors/restricted interests. In the absence of any medications known to improve core symptom domains, parents often use complementary alternative treatments, including omega-3 fatty acid supplements. En ligne : http://dx.doi.org/10.1186/s13229-015-0010-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=277 Review of neuroimaging in Autism Spectrum Disorders: what have we learned and where we go from here / Evdokia ANAGNOSTOU in Molecular Autism, (April 2011)
PermalinkRigor in science and science reporting: updated guidelines for submissions to Molecular Autism / Joseph D. BUXBAUM in Molecular Autism, 10 (2019)
PermalinkSpecificity of autonomic arousal to anxiety in children with autism spectrum disorder / Tabitha A. CHIU in Autism Research, 9-4 (April 2016)
PermalinkSystematic review of clinical guidance documents for autism spectrum disorder diagnostic assessment in select regions / M. PENNER in Autism, 22-5 (July 2018)
PermalinkTransdiagnostic Patterns of Sensory Processing in Autism and ADHD / Anahid POURTOUSI ; Connie YANG ; Zining DING ; Bobby STOJANOSKI ; Evdokia ANAGNOSTOU ; Robert NICOLSON ; Elizabeth KELLEY ; Stelios GEORGIADES ; Jennifer CROSBIE ; Russell SCHACHAR ; Muhammad AYUB ; Ryan A. STEVENSON in Journal of Autism and Developmental Disorders, 54-1 (January 2024)
PermalinkUsing the COM-B Model and Theoretical Domains Framework to Understand Workplace Disclosure Experiences, Influencers, and Needs Among Autistic Young Adults / Shauna KINGSNORTH ; Bonnie KIRSH ; Evdokia ANAGNOSTOU ; Sally LINDSAY in Journal of Autism and Developmental Disorders, 53-12 (December 2023)
PermalinkWeighty Conversations: Caregivers', Children's, and Clinicians' Perspectives and Experiences of Discussing Weight-Related Topics in Healthcare Consultations / P. JACHYRA in Autism Research, 11-11 (November 2018)
PermalinkWhite matter and development in children with an autism spectrum disorder / Kathleen M. MAK-FAN in Autism, 17-5 (September 2013)
PermalinkWidespread White Matter Differences in Children and Adolescents with Autism Spectrum Disorder / V. M. VOGAN in Journal of Autism and Developmental Disorders, 46-6 (June 2016)
Permalink